Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.

S'inscrire

BBIO BridgeBio Pharma Inc

28,00

-0,85 (-2,95%)

01 Juin 2024 - Fermé

Retardé de 15 minutes

Form 5 - Annual statement of changes in beneficial ownership of securities

BridgeBio Pharma (NASDAQ:BBIO)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024

Plus de graphiques de la Bourse BridgeBio Pharma

BridgeBio Pharma (NASDAQ:BBIO)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024

Plus de graphiques de la Bourse BridgeBio Pharma

Actualités BridgeBio Pharma Inc

Additional Data Showing Acoramidis Increases Serum Transthyretin Which is Associated with Improved Cardiovascular Outcomes Presented at ISA from BridgeBio Pharma’s Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Mercredi 29 Mai 2024 ( il y a 4 jours) • GlobeNewswire Inc.

BridgeBio Pharma to Present Additional Analyses from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the 2024 ISA Meeting
Vendredi 24 Mai 2024 ( il y a 1 semaine) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Vendredi 17 Mai 2024 ( il y a 2 semaines) • Edgar (US Regulatory)

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Mercredi 15 Mai 2024 ( il y a 3 semaines) • GlobeNewswire Inc.

BridgeBio Pharma to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2024
Mardi 14 Mai 2024 ( il y a 3 semaines) • GlobeNewswire Inc.

BridgeBio Pharma Presents Additional Data and Analyses from its Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at ESC-HF, Including That Acoramidis Treatment Significantly Reduced All-Cause Mortality in a Pre-specified Sensiti
Lundi 13 Mai 2024 ( il y a 3 semaines) • GlobeNewswire Inc.

BridgeBio Pharma Reports First Quarter 2024 Financial Results and Business Update
Jeudi 2 Mai 2024 ( il y a 1 mois) • GlobeNewswire Inc.

BridgeBio launches BridgeBio Oncology Therapeutics (BBOT) with $200M of private external capital to accelerate the development of its novel precision oncology pipeline
Jeudi 2 Mai 2024 ( il y a 1 mois) • GlobeNewswire Inc.

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Mercredi 10 Avril 2024 ( il y a 2 mois) • GlobeNewswire Inc.

BridgeBio Pharma Presents Cardiac Magnetic Resonance (CMR) Imaging Evidence Consistent with Clinical Improvement Observed in the ATTRibute-CM Phase 3 Study in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Dimanche 7 Avril 2024 ( il y a 2 mois) • GlobeNewswire Inc.

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Mercredi 20 Mars 2024 ( il y a 2 mois) • GlobeNewswire Inc.

Form 424B5 - Prospectus [Rule 424(b)(5)]
Mercredi 6 Mars 2024 ( il y a 3 mois) • Edgar (US Regulatory)

Plus d'articles sur BridgeBio Pharma Inc

JP Morgan Chase

Lvmh Moet Hennessy Louis...

Delayed Upgrade Clock

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales